HEMOSNOW
HEMOSNOW: A revolution in haemostatic technology to stop bleeding in delicate surgery and enhance patient recovery
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0HEMOSNOW project word cloud
Explore the words cloud of the HEMOSNOW project. It provides you a very rough idea of what is the project "HEMOSNOW" about.
Project "HEMOSNOW" data sheet
The following table provides information about the project.
| Coordinator |
BIOM'UP SA
Organization address contact info |
| Coordinator Country | France [FR] |
| Project website | https://www.biomup.com/ |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-1 |
| Funding Scheme | SME-1 |
| Starting year | 2019 |
| Duration (year-month-day) | from 2019-05-01 to 2019-08-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | BIOM'UP SA | FR (SAINT-PRIEST) | coordinator | 50˙000.00 |
Map
Project objective
Excessive blood loss during surgery is a major concern - 42% of all patients who experience excessive blood loss during surgery die. Excessive bleeding contributes to longer hospital stays and delayed post-operative recovery. This incurs costs for both hospitals and patients with increased operating room time estimated to cost €1,542 - €2,554/hour while increased hospital stay is estimated at €1,038/day. Conventional techniques used to control excessive bleeding such as electrocautery are not always feasible and are often restricted to accessible vessels of a minimum size. This limits their applicability and contributes to postoperative drainage and pain. Haemostatic agents are formulations designed to arrest bleeding by supplementing the normal haemostatic mechanism of the body. Most haemostats currently used by surgeons to control bleeding have lengthy preparation times, are difficult to apply and stick to surgical instruments which limits their suitable application. In response, Biom’up has developed HEMOSNOW, a unique haemostatic powder formulation capable of stopping level 1 & 2 bleeding on the SPOTGRADE scale (developed and patented by Biom’up to quantitatively determine bleeding from surgical wounds). This collagen-based powder is ready to use and stops bleeding within 6minutes. It will equip surgeons with an effective tool for rapid and effective haemostasis, reduce operational procedure time and reduce the risk of surgical errors which occur when the surgeon’s vision is obscured by excessive blood. Patients benefit through lower healthcare costs, faster recovery and lower risks associated with blood transfusion. Biom’up is a French biotech company founded in 2005 which specialises in collagen-based resorbable medical devices for biosurgery. This project is expected to generate an accumulated revenue of €5 million in 5 years post commercialisation and employ 250 people.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HEMOSNOW" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "HEMOSNOW" are provided by the European Opendata Portal: CORDIS opendata.